Sanofi culls pipeline dud, still looking to out-license unwanted later-stage meds

Sanofi is culling a Regeneron-partnered med and still looking for partners for two unwanted pipeline candidates as the Big Pharma continues to reshuffle its R&D priorities.

This is according to its first-quarter update (PDF) posted early Friday morning. We already knew that efpeglenatide, a long-acting GLP-1 agonist for Type 2 diabetes, was on the chopping block when the French Big Pharma, alongside partner Hanmi, said late last year they were looking for a new partner to sell the med.